MRK Oct 2024 65.000 put
OPR - OPR Delayed price. Currency in USD
Add to watchlist
As of 03:51PM EDT. Market open.
| Previous close | 0.3000 |
| Open | 0.3000 |
| Bid | 0.0000 |
| Ask | 0.2700 |
| Strike | 65.00 |
| Expiry date | 2024-10-18 |
| Day's range | 0.3000 - 0.3000 |
| Contract range | N/A |
| Volume | |
| Open interest | 1 |
ReutersMerck nears $1.3 billion cash deal for eye-drug company EyeBio, WSJ reports
Merck did not immediately respond to Reuters' request for a comment, while Eyebiotech declined to comment. Eyebiotech is a clinical stage opthalmology company, with operations in the U.S. and the UK, that seeks to treat patients with sight-threatening diseases. Its major drug in clinical stage, Restoret, aims to treat retinal diseases characterized by leakage that can lead to impaired vision.
- Investing.com
Merck nears $1.3 bln takeover of Eyebiotech- WSJ
Investing.com-- Merck&Company Inc (NYSE:MRK) is close to entering a $1.3 billion deal to buy Eyebiotech, granting the pharmaceutical giant entry into the rapidly growing eyecare market, the Wall Street Journal reported on Tuesday.
Business WireMerck Announces Third-Quarter 2024 Dividend
RAHWAY, N.J., May 28, 2024--Merck Announces Third-Quarter 2024 Dividend
© 2024 Yahoo. All rights reserved.